The rise of DOLs doesn’t mean pharma should upend KOL approach.
Read Roberts
Advertisement
Director, KOL Data Solutions, PRECISIONscientia
Articles by Read Roberts
Advertisement
Latest Updated Articles
Food for Thought: Make Room for Multiple OpinionsPublished: March 10th 2023 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Eli Lilly’s and Novo’s Stocks React to President Trump’s Comments on GLP-1 Prices
2
All of the Medications Announced as Part of FDA’s National Priority Voucher Program
3
Autonomous Omnichannel: When AI Thinks for Pharma Marketing
4
EMD Serono Announces Agreement with Trump Administration Increasing Access to In Vitro Fertilization Therapies for US Patients
5
